Research Article

High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration

Table 3

Correlation between PDLIM2 protein expression and clinicopathological characteristics.

VariablesPDL1M2 expressionTotal value
LowHigh

Age (year)0.0060.939
 ≤70312455
 >70443579
Gleason score7.0470.029
 621728
 7182442
 >7362864
T stage4.0090.045
 T1, T2, T3311849
 T461117
N stage4.0630.044
 N06746113
 N171320
34βE121.0110.315
 Low7052122
 High415
AR2.1060.147
 Low303
 High7050120
CK5/61.5110.219
 Low6449113
 High202
Ki674.5140.034
 Low492574
 High232649
P504s1.6530.199
 Low516
 High6751118
P530.0330.855
 Low523688
 High161228
P630.0960.757
 Low7152123
 High213
PSA0.9260.336
 Low13619
 High6046106
PSAP1.6530.199
 Low516
 High6751118
SMA2.9810.084
 Low544094
 High10212
TOPO-II0.3240.569
 Low121123
 High433073
ERG0.1590.690
 Low463884
 High111122
P1700.0670.795
 Low523890
 High538

Statistically significant (). Abbreviations: AR: androgen receptor; PSA: prostate-specific antigen; PSAP: prostate-specific alkaline phosphatase; SMA: alpha-smooth muscle actin; TOPO-II: topoisomerase II; ERG: ETS-related gene.